Overview

Treatment of Vasomotor Symptoms in Korean Post Menopausal Women

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
Study to demonstrate that the therapeutic efficacy of Angeliq® is better than placebo in Korean postmenopausal women with hot flushes and other climacteric symptoms. Safety and tolerability of Angeliq.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Drospirenone
Drospirenone and ethinyl estradiol combination
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Polyestradiol phosphate